# OnCo record antiangiogenic-toxicities (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/antiangiogenic-toxicities/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "antiangiogenic-toxicities" ;
  schema:name "Anti-VEGF class toxicities (hypertension, proteinuria, bleeding, perforation)"@en ;
  schema:alternateName "proteinuria"@en, "bleeding"@en, "haemorrhage"@en, "hemorrhage"@en, "bleeding events"@en, "bleeding risk"@en, "haemoptysis"@en, "epistaxis"@en, "gastrointestinal perforation"@en, "GI perforation"@en, "perforation"@en, "bowel perforation"@en, "fistula"@en, "fistula formation"@en, "wound healing"@en, "wound-healing complications"@en, "impaired wound healing"@en, "wound dehiscence"@en, "reversible posterior leukoencephalopathy"@en, "PRES"@en, "VEGF inhibitor toxicity"@en, "anti-VEGF toxicity"@en, "hold 28 days around surgery"@en ;
  schema:description "The shared side effects of drugs that block blood vessel growth (bevacizumab, ramucirumab and VEGFR kinase inhibitors): high blood pressure, protein leaking into the urine, nosebleeds and more serious bleeding, slow wound healing, and rarely holes in the bowel."@en ;
  schema:url <https://onco.cc/terms/antiangiogenic-toxicities/> ;
  schema:dateModified "2026-09-09"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Bevacizumab#Adverse_effects> ;
  schema:citation <https://en.wikipedia.org/wiki/Bevacizumab#Adverse_effects> ;
  onco:related <https://onco.cc/terms/vte/>, <https://onco.cc/terms/hand-foot-syndrome/>, <https://onco.cc/terms/tki-term/>, <https://onco.cc/terms/surgical-morbidity/> ;
  onco:sections <https://onco.cc/fronts/supportive-care/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/> ;
  onco:drugs <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/cabozantinib/>, <https://onco.cc/drugs/regorafenib/> .